The App4Independence (A4i) is a patent-pending, validated digital therapeutic and digital biomarker platform for severe mental illnesses (SMIs). The A4i app and clinical portal collects data for clinical decision support, engagement enhancement and readmission risk identification. Using ambient, NLP and engagement data, A4i improves outcomes and provides relapse risk detection. A joint venture between Canada's largest mental health hospital (CAMH) and MEMOTEXT Corp., A4i has shown significant improvements in several outcome domains related to schizophrenia and psychoses recovery.

A4i logo



Event details

Date: October 24 - 26, 2022

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences


14 in total